Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.85 3.26% 0.09
PIRS closed up 3.26 percent on Wednesday, August 5, 2020, on 46 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical PIRS trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 3.26%
Oversold Stochastic Weakness 3.26%
Stochastic Buy Signal Bullish 5.17%
Inside Day Range Contraction 5.17%
Wide Bands Range Expansion 5.17%
Oversold Stochastic Weakness 5.17%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Medicine Chemistry Cancers Dialysis Membrane Technology Asthma Chronic Kidney Disease Anatomy Inflammatory Diseases Kidney Diseases End Stage Renal Disease Hepatology Kidney Central Nervous System Tumors Hepcidin Treatment Of Various Types Of Cancers

Is PIRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.97
52 Week Low 1.6
Average Volume 434,130
200-Day Moving Average 3.16
50-Day Moving Average 3.13
20-Day Moving Average 2.94
10-Day Moving Average 2.78
Average True Range 0.22
ADX 13.91
+DI 16.16
-DI 19.47
Chandelier Exit (Long, 3 ATRs ) 2.87
Chandelier Exit (Short, 3 ATRs ) 3.21
Upper Bollinger Band 3.39
Lower Bollinger Band 2.50
Percent B (%b) 0.39
BandWidth 30.15
MACD Line -0.11
MACD Signal Line -0.09
MACD Histogram -0.0191
Fundamentals Value
Market Cap 126.28 Million
Num Shares 44.3 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -4.01
Price-to-Sales 31.97
Price-to-Book 22.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.12
Resistance 3 (R3) 3.10 2.98 3.08
Resistance 2 (R2) 2.98 2.91 3.00 3.06
Resistance 1 (R1) 2.92 2.87 2.95 2.94 3.04
Pivot Point 2.80 2.80 2.82 2.82 2.80
Support 1 (S1) 2.74 2.73 2.77 2.76 2.66
Support 2 (S2) 2.62 2.69 2.64 2.64
Support 3 (S3) 2.56 2.62 2.63
Support 4 (S4) 2.58